Close
Achema middle east
swop processing & packaging

European Union signs Remdesivir deal with Gilead

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Thermo Fisher Scientific to Accelerate Life Science Breakthroughs with OpenAI

WALTHAM, Mass. (October 16, 2025) – Thermo Fisher Scientific Inc....

Why Anti-Wrinkle Injections Are Gaining Popularity in Ireland

Over the past decade, Ireland has seen a significant...

Driving Excellence in Pharmaceutical Production with Advanced Pharmaceutical Cooling Systems

Introduction In pharmaceutical manufacturing, every degree matters. Process cooling is...

AstraZeneca and Daiichi Report Datroway Efficacy for TNBC

Datroway, a cancer drug developed by AstraZeneca and Daiichi...

The European Union’s executive said that it has signed a contract with Gilead for its COVID-19 medicine remdesivir that would cover 30,000 patients in the bloc from early August.

“The Commission signed a contract with the pharmaceutical company Gilead for ensuring treatment doses of Veklury – the brand name for remdesivir. As of early August onwards, batches of this medicine Veklury will be made available to member states and the UK,” a spokeswoman for the European Commission, Dana Spinant, told a regular news briefing.

She said the contract was worth 63 million euros ($73.99 million) and would provide treatment to 30,000 patients with severe COVID-19 symptoms.

“This first batch will therefore address just immediate needs. At the same time, the Commission is also now preparing joint procurement for further supplies of this medicine, which will cover additional needs from October onwards,” she said.

Latest stories

Related stories

Thermo Fisher Scientific to Accelerate Life Science Breakthroughs with OpenAI

WALTHAM, Mass. (October 16, 2025) – Thermo Fisher Scientific Inc....

Why Anti-Wrinkle Injections Are Gaining Popularity in Ireland

Over the past decade, Ireland has seen a significant...

Driving Excellence in Pharmaceutical Production with Advanced Pharmaceutical Cooling Systems

Introduction In pharmaceutical manufacturing, every degree matters. Process cooling is...

AstraZeneca and Daiichi Report Datroway Efficacy for TNBC

Datroway, a cancer drug developed by AstraZeneca and Daiichi...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »